DNA-based vaccines: the future of multiple sclerosis therapy?

References

• Martin R, McFarland HF, McFarlin DE. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol.10, 153–187 (1992).
   PubMed Web of Science ®Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N. Engl. J. Med.343(13), 938–952 (2000).
   PubMed Web of Science ®Google Scholar
• Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple sclerosis. Clin. Neurol. Neurosurg.104(3), 182–191 (2002).
   PubMed Web of Science ®Google Scholar
• Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol. Sci.22(2), 117–139 (2001).
   PubMed Web of Science ®Google Scholar
• Kurtzke JF, Beebe GW, Norman JE Jr. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology29(9 Pt 1), 1228–1235 (1979).
   PubMed Web of Science ®Google Scholar
• Sadovnick AD, Baird PA. Sex ratio in offspring of patients with multiple sclerosis. N. Engl. J. Med.306(18), 1114–1115 (1982).
   PubMed Web of Science ®Google Scholar
• Schiffer RB, Weitkamp LR, Wineman NM, Guttormsen S. Multiple sclerosis and affective disorder. Family history, sex, and HLA-DR antigens. Arch. Neurol.45(12), 1345–1348 (1988).
   PubMed Web of Science ®Google Scholar
• Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol.55(1), 65–71 (2004).
   PubMed Web of Science ®Google Scholar
• Poser S, Raun NE, Poser W. Age at onset, initial symptomatology and the course of multiple sclerosis. Acta. Neurol. Scand.66(3), 355–362 (1982).
   PubMed Web of Science ®Google Scholar
• Kurtzke JF, Page WF, Murphy FM, Norman JE Jr. Epidemiology of multiple sclerosis in US veterans. 4. Age at onset. Neuroepidemiology11(4–6), 226–235 (1992).
   PubMed Web of Science ®Google Scholar
• Liguori M, Marrosu MG, Pugliatti M et al. Age at onset in multiple sclerosis. Neurol. Sci.21(4 Suppl. 2), S825–S829 (2000).
   Google Scholar
• Steinman L. Multiple sclerosis: a two-stage disease. Nat. Immunol.2(9), 762–764 (2001).
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: relations between study investigators, advisors, and sponsors. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology48(3), 572–574 (1997).
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology46(4), 907–911 (1996).
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology33(11), 1444–1452 (1983).
   PubMed Web of Science ®Google Scholar
• Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med.338(5), 278–285 (1998).
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Wiendl H, Hemmer B, Hartung HP. Treatment and treatment trials in multiple sclerosis. Curr. Opin. Neurol.20(3), 286–293 (2007).
   PubMed Web of Science ®Google Scholar
• Robertson JS, Griffiths E. Assuring the quality, safety, and efficacy of DNA vaccines. Methods Mol. Med.127, 363–374 (2006).
   PubMedGoogle Scholar
• Donnelly JJ, Wahren B, Liu MA. DNA vaccines: progress and challenges. J. Immunol.175(2), 633–639 (2005).
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application, and optimization. Annu. Rev. Immunol.18, 927–974 (2000).
   PubMed Web of Science ®Google Scholar
• Fu TM, Ulmer JB, Caulfield MJ et al. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes. Mol. Med.3(6), 362–371 (1997).
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Calarota SA, Lori F. The potential of topical DNA vaccines adjuvanted by cytokines. Expert Opin. Biol. Ther.7(10), 1563–1574 (2007).
   PubMed Web of Science ®Google Scholar
• Spies B, Hochrein H, Vabulas M et al. Vaccination with plasmid DNA activates dendritic cells via Toll-like receptor 9 (TLR9) but functions in TLR9-deficient mice. J. Immunol.171(11), 5908–5912 (2003).
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Vollmer T, Antel J et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with a DNA encoding myelin basic protein in a randomized, placebo-controlled Phase I/II trial. Arch. Neurol.64(10), 1407–1415 (2007).
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Torres CA, Ohashi PS, Robinson HL, Barber BH. The dominant role of bone marrow-derived cells in CTL induction following plasmid DNA immunization at different sites. J. Immunol.159(1), 11–14 (1997).
   PubMed Web of Science ®Google Scholar
• Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J. Exp. Med.189(1), 169–178 (1999).
   PubMed Web of Science ®Google Scholar
• Casares S, Inaba K, Brumeanu TD, Steinman RM, Bona CA. Antigen presentation by dendritic cells after immunization with DNA encoding a major histocompatibility complex class II-restricted viral epitope. J. Exp. Med.186(9), 1481–1486 (1997).
   PubMed Web of Science ®Google Scholar
• Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol.8, 579–621 (1990).
   PubMed Web of Science ®Google Scholar
• Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature346(6280), 183–187 (1990).
   PubMed Web of Science ®Google Scholar
• Martin R, Jaraquemada D, Flerlage M et al. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol.145(2), 540–548 (1990).
   PubMed Web of Science ®Google Scholar
• Jingwu Z, Medaer R, Hashim GA, Chin Y, Berg-Loonen E, Raus JC. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann. Neurol.32(3), 330–338 (1992).
   PubMed Web of Science ®Google Scholar
• Joshi N, Usuku K, Hauser SL. The T-cell response to myelin basic protein in familial multiple sclerosis: diversity of fine specificity, restricting elements, and T-cell receptor usage. Ann. Neurol.34(3), 385–393 (1993).
   PubMed Web of Science ®Google Scholar
• Lovett-Racke AE, Trotter JL, Lauber J, Perrin PJ, June CH, Racke MK. Decreased dependence of myelin basic protein-reactive T cells on CD28- mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J. Clin. Invest.101(4), 725–730 (1998).
   PubMed Web of Science ®Google Scholar
• Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med.354(6), 610–621 (2006).
   PubMed Web of Science ®Google Scholar
• Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol.136(7), 2348–2357 (1986).
   PubMed Web of Science ®Google Scholar
• Panitch HS, Hirsch RL, Haley AS, Johnson KP. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet1(8538), 893–895 (1987).
   PubMed Web of Science ®Google Scholar
• Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a Phase II clinical trial with an altered peptide ligand. Nat. Med.6(10), 1167–1175 (2000).
   PubMed Web of Science ®Google Scholar
• Ferber IA, Brocke S, Taylor-Edwards C et al. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol.156(1), 5–7 (1996).
   PubMed Web of Science ®Google Scholar
• Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA. IFN-γ plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol.157(8), 3223–3227 (1996).
   PubMed Web of Science ®Google Scholar
• Genain CP, Abel K, Belmar N et al. Late complications of immune deviation therapy in a nonhuman primate. Science274(5295), 2054–2057 (1996).
   PubMed Web of Science ®Google Scholar
• Cannella B, Raine CS. Multiple sclerosis: cytokine receptors on oligodendrocytes predict innate regulation. Ann. Neurol.55(1), 46–57 (2004).
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol.6(11), 1123–1132 (2005).
   PubMed Web of Science ®Google Scholar
• Lock C, Hermans G, Pedotti R et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med.8(5), 500–508 (2002).
   PubMed Web of Science ®Google Scholar
• Kebir H, Kreymborg K, Ifergan I et al. Human Th17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. Nat. Med.13(10), 1173–1175 (2007).
   PubMed Web of Science ®Google Scholar
• Giuliani F, Goodyer CG, Antel JP, Yong VW. Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol.171(1), 368–379 (2003).
   PubMed Web of Science ®Google Scholar
• Babbe H, Roers A, Waisman A et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J. Exp. Med.192(3), 393–404 (2000).
   PubMed Web of Science ®Google Scholar
• Jacobsen M, Cepok S, Quak E et al. Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain125(Pt 3), 538–550 (2002).
   PubMed Web of Science ®Google Scholar
• Skulina C, Schmidt S, Dornmair K et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc. Natl Acad. Sci. USA101(8), 2428–2433 (2004).
   PubMed Web of Science ®Google Scholar
• Medana IM, Gallimore A, Oxenius A, Martinic MM, Wekerle H, Neumann H. MHC class I-restricted killing of neurons by virus-specific CD8+ T lymphocytes is effected through the Fas/FasL, but not the perforin pathway. Eur. J. Immunol.30(12), 3623–3633 (2000).
   PubMed Web of Science ®Google Scholar
• Medana I, Martinic MA, Wekerle H, Neumann H. Transection of major histocompatibility complex class I-induced neurites by cytotoxic T lymphocytes. Am. J. Pathol.159(3), 809–815 (2001).
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science299(5609), 1057–1061 (2003).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Powrie F. Emerging challenges in regulatory T cell function and biology. Science317(5838), 627–629 (2007).
   PubMed Web of Science ®Google Scholar
• Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med.199(7), 971–979 (2004).
   PubMed Web of Science ®Google Scholar
• Haas J, Hug A, Viehover A et al. Reduced suppressive effect of CD4+CD25 high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol.35(11), 3343–3352 (2005).
   PubMed Web of Science ®Google Scholar
• Kumar M, Putzki N, Limmroth V et al. CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J. Neuroimmunol.180(1–2), 178–184 (2006).
   PubMed Web of Science ®Google Scholar
• Huan J, Culbertson N, Spencer L et al. Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res.81(1), 45–52 (2005).
   PubMed Web of Science ®Google Scholar
• Feger U, Luther C, Poeschel S, Melms A, Tolosa E, Wiendl H. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin. Exp. Immunol.147(3), 412–418 (2007).
   PubMed Web of Science ®Google Scholar
• Venken K, Hellings N, Hensen K et al. Secondary progressive in contrast to relapsing–remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression. J. Neurosci. Res.83(8), 1432–1446 (2006).
   PubMed Web of Science ®Google Scholar
• Owens GP, Bennett JL, Gilden DH, Burgoon MP. The B cell response in multiple sclerosis. Neurol. Res.28(3), 236–244 (2006).
   PubMed Web of Science ®Google Scholar
• Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol.47(6), 707–717 (2000).
   PubMed Web of Science ®Google Scholar
• Cepok S, Rosche B, Grummel V et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain128(Pt 7), 1667–1676 (2005).
   PubMed Web of Science ®Google Scholar
• Kabat EA, Freedman DA. A study of the crystalline albumin, gamma globulin and total protein in the cerebrospinal fluid of 100 cases of multiple sclerosis and in other diseases. Am. J. Med. Sci.219(1), 55–64 (1950).
   PubMed Web of Science ®Google Scholar
• Villar LM, Masjuan J, Gonzalez-Porque P et al. Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology58(5), 824–826 (2002).
   PubMed Web of Science ®Google Scholar
• Villar LM, Masjuan J, Gonzalez-Porque P et al. Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology59(4), 555–559 (2002).
   PubMed Web of Science ®Google Scholar
• Villar LM, Masjuan J, Gonzalez-Porque P et al. Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann. Neurol.53(2), 222–226 (2003).
   PubMed Web of Science ®Google Scholar
• Corcione A, Casazza S, Ferretti E et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc. Natl Acad. Sci. USA101(30), 11064–11069 (2004).
   PubMed Web of Science ®Google Scholar
• Ebers GC, Kukay K, Bulman DE et al. A full genome search in multiple sclerosis. Nat. Genet.13(4), 472–476 (1996).
   PubMed Web of Science ®Google Scholar
• Haines JL, Ter Minassian M, Bazyk A et al. A complete genomic screen for multiple sclerosis underscores a role for the major histocompatability complex. The Multiple Sclerosis Genetics Group. Nat. Genet.13(4), 469–471 (1996).
   PubMed Web of Science ®Google Scholar
• Sawcer S, Jones HB, Feakes R et al. A genome screen in multiple sclerosis reveals susceptibility loci on chromosome 6p21 and 17q22. Nat. Genet.13(4), 464–468 (1996).
   PubMed Web of Science ®Google Scholar
• Kuokkanen S, Sundvall M, Terwilliger JD et al. A putative vulnerability locus to multiple sclerosis maps to 5p14-p12 in a region syntenic to the murine locus Eae2. Nat. Genet.13(4), 477–480 (1996).
   PubMed Web of Science ®Google Scholar
• Barcellos LF, Oksenberg JR, Begovich AB et al. HLA-DR2 Dose effect on susceptibility to multiple sclerosis and influence on disease course. Am. J. Hum. Genet.72(3), 710–716 (2003).
   PubMed Web of Science ®Google Scholar
• Villoslada P, Barcellos LF, Rio J et al. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-β. J. Neuroimmunol.130(1–2), 194–201 (2002).
   PubMed Web of Science ®Google Scholar
• Celius EG, Harbo HF, Egeland T, Vartdal F, Vandvik B, Spurkiand A. Sex and age at diagnosis are correlated with the HLA-DR2, DQ6 haplotype in multiple sclerosis. J. Neurol. Sci.178(2), 132–135 (2000).
   PubMed Web of Science ®Google Scholar
• Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, Hillert J. HLA-DR15 is associated with lower age at onset in multiple sclerosis. Ann. Neurol.48(2), 211–219 (2000).
   PubMed Web of Science ®Google Scholar
• Weatherby SJ, Thomson W, Pepper L et al. HLA-DRB1 and disease outcome in multiple sclerosis. J. Neurol.248(4), 304–310 (2001).
   PubMed Web of Science ®Google Scholar
• Hensiek AE, Sawcer SJ, Feakes R et al. HLA-DR 15 is associated with female sex and younger age at diagnosis in multiple sclerosis. J. Neurol. Neurosurg. Psychiatr.72(2), 184–187 (2002).
   PubMed Web of Science ®Google Scholar
• Racke MK, Ratts RB, Arredondo L, Perrin PJ, Lovett-Racke A. The role of costimulation in autoimmune demyelination. J. Neuroimmunol.107(2), 205–215 (2000).
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med.192(7), 1027–1034 (2000).
   PubMed Web of Science ®Google Scholar
• Selenko-Gebauer N, Majdic O, Szekeres A et al. B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy. J. Immunol.170(7), 3637–3644 (2003).
   PubMed Web of Science ®Google Scholar
• Schreiner B, Mitsdoerffer M, Kieseier BC et al. Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis. J. Neuroimmunol.155(1–2), 172–182 (2004).
   PubMed Web of Science ®Google Scholar
• Prineas JW. Multiple sclerosis: presence of lymphatic capillaries and lymphoid tissue in the brain and spinal cord. Science203(4385), 1123–1125 (1979).
   PubMed Web of Science ®Google Scholar
• Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Aloisi F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol.14(2), 164–174 (2004).
   PubMed Web of Science ®Google Scholar
• Magliozzi R, Howell O, Vora A et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain130(Pt 4), 1089–1104 (2007).
   PubMed Web of Science ®Google Scholar
• Lanzavecchia A, Sallusto F. From synapses to immunological memory: the role of sustained T cell stimulation. Curr. Opin. Immunol.12(1), 92–98 (2000).
   PubMed Web of Science ®Google Scholar
• Stuve O, Cree BC, von Budingen HC et al. Approved and future pharmacotherapies for multiple sclerosis. Neurologist8, 290–301 (2002).
   PubMed Web of Science ®Google Scholar
• Mrass P, Weninger W. Immune cell migration as a means to control immune privilege: lessons from the CNS and tumors. Immunol. Rev.213, 195–212 (2006).
   PubMed Web of Science ®Google Scholar
• Youssef S, Wildbaum G, Maor G et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J. Immunol.161(8), 3870–3879 (1998).
   PubMed Web of Science ®Google Scholar
• Youssef S, Wildbaum G, Karin N. Prevention of experimental autoimmune encephalomyelitis by MIP-1a and MCP-1 naked DNA vaccines. J. Autoimmun.13(1), 21–29 (1999).
   PubMed Web of Science ®Google Scholar
• Garren H, Ruiz PJ, Watkins TA et al. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity15(1), 15–22 (2001).
   PubMed Web of Science ®Google Scholar
• Wildbaum G, Westermann J, Maor G, Karin N. A targeted DNA vaccine encoding fas ligand defines its dual role in the regulation of experimental autoimmune encephalomyelitis. J. Clin. Invest.106(5), 671–679 (2000).
   PubMed Web of Science ®Google Scholar
• Wildbaum G, Karin N. Augmentation of natural immunity to a pro-inflammatory cytokine (TNF-α) by targeted DNA vaccine confers long-lasting resistance to experimental autoimmune encephalomyelitis. Gene Ther.6(6), 1128–1138 (1999).
   PubMed Web of Science ®Google Scholar
• Mueller AM, Pedre X, Kleiter I, Hornberg M, Steinbrecher A, Giegerich G. Targeting fibroblast growth factor-inducible-14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol.159(1–2), 55–65 (2005).
   PubMed Web of Science ®Google Scholar
• Miyakoshi A, Yoon WK, Jee Y, Matsumoto Y. Characterization of the antigen specificity and TCR repertoire, and TCR-based DNA vaccine therapy in myelin basic protein-induced autoimmune encephalomyelitis in DA rats. J. Immunol.170(12), 6371–6378 (2003).
   PubMed Web of Science ®Google Scholar
• Kumar V, Maglione J, Thatte J, Pederson B, Sercarz E, Ward ES. Induction of a type 1 regulatory CD4 T cell response following V β 8.2 DNA vaccination results in immune deviation and protection from experimental autoimmune encephalomyelitis. Int. Immunol.13(6), 835–841 (2001).
   PubMed Web of Science ®Google Scholar
• Lobell A, Weissert R, Eltayeb S, Svanholm C, Olsson T, Wigzell H. Presence of CpG DNA and the local cytokine milieu determine the efficacy of suppressive DNA vaccination in experimental autoimmune encephalomyelitis. J. Immunol.163(9), 4754–4762 (1999).
   PubMed Web of Science ®Google Scholar
• Lobell A, Weissert R, Storch MK et al. Vaccination with DNA encoding an immunodominant myelin basic protein peptide targeted to Fc of immunoglobulin G suppresses experimental autoimmune encephalomyelitis. J. Exp. Med.187(9), 1543–1548 (1998).
   PubMed Web of Science ®Google Scholar
• Wefer J, Harris RA, Lobell A. Protective DNA vaccination against experimental autoimmune encephalomyelitis is associated with induction of IFNβ. J. Neuroimmunol.149(1–2), 66–76 (2004).
   PubMed Web of Science ®Google Scholar
• Selmaj K, Kowal C, Walczak A, Nowicka J, Raine CS. Naked DNA vaccination differentially modulates autoimmune responses in experimental autoimmune encephalomyelitis. J. Neuroimmunol.111(1–2), 34–44 (2000).
   PubMed Web of Science ®Google Scholar
• Sakudo A, Lee DC, Nishimura T et al. Octapeptide repeat region and N-terminal half of hydrophobic region of prion protein (PrP) mediate PrP-dependent activation of superoxide dismutase. Biochem. Biophys. Res. Commun.326(3), 600–606 (2005).
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol.50(1), 121–127 (2001).
   PubMed Web of Science ®Google Scholar